Novel Predicted B-Cell Epitopes of PSMA for Development of Prostate Cancer Vaccine

Hashemzadeh, Pejman; Ghorbanzadeh, Vajihe; Otaghsara, Seyede Maryam Valizadeh; Dariushnejad, Hassan

doi:10.1007/s10989-019-09954-9

Cited by 7 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSMA is being explored as a promising target for prostate cancer vaccines due to its molecular properties, and abundant expression on the surface of prostate cancer cells, and limited expression in other tissues. 53,54 TherapeuTic advances in Medical…”

Section: Cancer Vaccinesmentioning

confidence: 99%

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review

Martin

Dorff

2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

The lack of success in prostate cancer from immune checkpoint inhibitors, which is likely multifactorial, has led to the development and investigation of a number of other novel immunotherapeutic techniques, including antibody–drug conjugates, T-cell redirected bispecific therapies, cancer vaccines and chimeric antigen receptor T-cell therapies. Prostate-specific membrane antigen (PSMA) is a tumour-associated antigen (TAA) that is highly expressed in metastatic prostate cancer and has been validated as an effective target for radionuclide treatment. But while PSMA has thus far been the ‘front runner’ target for these novel immunotherapeutic techniques, it may not be the ideal target for immunotherapy and there are other potential targetable TAAs that will require further exploration. This review will focus on these various PSMA-directed therapies, as well as other potential targets for immunotherapy beyond PSMA.

show abstract

Section: Cancer Vaccinesmentioning

confidence: 99%

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review

Martin

Dorff

2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…However, this approach continues to be investigated, given its potential efficacy, minimal side effects, limited cost, and easy synthesis. Specifically, PSMA is being considered as an appropriate target for the development of PCa vaccines [191] . Using new computational tools to select suitable B-cell epitopes with high antigenicity, the "673RHVIYAPSSHNKYAGE25" peptide was predicted as having the best binding affinity.…”

Section: Psma-directed Vaccinesmentioning

confidence: 99%

“…Using new computational tools to select suitable B-cell epitopes with high antigenicity, the “673RHVIYAPSSHNKYAGE25” peptide was predicted as having the best binding affinity. Future steps involve synthesis of the peptide and testing its in vivo efficacy as a potential PSMA-directed vaccine [ 192 ] .…”

Section: Emerging Treatments Targeting Mcrpcmentioning

confidence: 99%

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo

Yehya¹,

Ghamlouche²,

Zahwe³

et al. 2022

Cancer Drug Resist

View full text Add to dashboard Cite

Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality in men globally. Despite improvements in the diagnosis and treatment of PCa, a significant proportion of patients with high-risk localized disease and all patients with advanced disease at diagnosis will experience progression to metastatic castration-resistant prostate cancer (mCRPC). Multiple drugs are now approved as the standard of care treatments for patients with mCRPC that have been shown to prolong survival. Although the majority of patients will respond initially, primary and secondary resistance to these therapies make mCRPC an incurable disease. Several molecular mechanisms underlie the development of mCRPC, with the androgen receptor (AR) axis being the main driver as well as the key drug target. Understanding resistance mechanisms is crucial for discovering novel therapeutic strategies to delay or reverse the progression of the disease. In this review, we address the diverse mechanisms of drug resistance in mCRPC. In addition, we shed light on emerging targeted therapies currently being tested in clinical trials with promising potential to overcome mCRPC-drug resistance.

show abstract

“…Given its ideal features, PSMA continues to be explored as a target for prostate cancer vaccines. 74…”

Section: Part 2: Psma-targeted Immunotherapymentioning

confidence: 99%

“…Given its ideal features, PSMA continues to be explored as a target for prostate cancer vaccines. 74 Bispecific T-cell re-directed therapy One strategy to overcome the underlying immunosuppressive TME in prostate cancer is to activate T-cells in the presence of prostate cancer.…”

Section: Chimeric Antigen Receptor T Cellsmentioning

confidence: 99%

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

et al. 2021

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this protein have been created over the past decade and numerous clinical studies have positively demonstrated the tolerance and efficacy of radiolabeled prostate-specific membrane antigen ligands for PSMA radioligand therapy (PRLT). Preliminary results are encouraging that PRLT will become an important addition to the current therapeutic options in a number of settings. Improvement in radiopharmaceutical targeting and combination with other oncological agents are under investigation to further improve its therapeutic efficacy. These encouraging results have led to the development of other therapies using PSMA as a target, such as PSMA–targeted chimeric antigen receptor T-cells, PSMA–targeted antibody drug conjugates, and PSMA–targeted bi-specific T-cell-directed therapy. This narrative review details the current state and advancements in prostate-specific membrane antigen targeting in prostate cancer treatment.

show abstract

Novel Predicted B-Cell Epitopes of PSMA for Development of Prostate Cancer Vaccine

Cited by 7 publications

References 20 publications

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

Contact Info

Product

Resources

About